Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

NIMBUS trial

print
PRINT
insite
SEARCH

In the phase 3 NIMBUS trial, patients with high-grade non-muscle invasive bladder carcinoma were randomly assigned to receive either the standard or a reduced number of Bacillus Calmette-Guérin doses with a view to establish the noninferiority of the reduced number of infusions.

Results presented at ASCO GU 2020 showed that the standard dose is superior:

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript


print
PRINT

Related content

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert highlights from ASCO GU 2020
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

ASCO GU 2020 conference hub

ASCO GU 2020 conference hub

Access all the latest news and expert video commentary from the 2020 Genitourinary Cancers Symposium in San Francisco, USA.

Register for conference alerts

Receive the latest content direct to your inbox.

Image Credits